Development of the new clinical cure to overcome pemetrexed tolerance for malignant pleural mesothelioma

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461159
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Tottori University
• Principal Investigator: SHIMIZU EIJI 鳥取大学, 医学部, 教授 (50187449)
• Co-Investigator(Kenkyū-buntansha): 高田 美也子 鳥取大学, 医学部, プロジェクト研究員 (50523643) ; 千酌 浩樹 鳥取大学, 医学部附属病院, 教授 (90283994)
• Co-Investigator(Renkei-kenkyūsha): YAMAGUCHI Kousuke 鳥取大学, 医学部附属病院, 助教 (60529402) ; MIYAKE Naomi 鳥取大学, 医学部, 特任教員 (90747205)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 悪性胸膜中皮腫 / ペメトレキセド / 臨床呼吸器学

Outline of Final Research Achievements

Pemetrexed is used as chemotherapy of the malignant pleural mesothelioma, however, the resistance for pemetrexed is now increasing problem. Therefore, we made pemetrexed-resistant cell lines. Using these cell lines, we searched for the resistant related molecules and pathways and a new clinical cure to overcome pemetrexed resistance. As a result, we found that increasment of the expression of Akt in resistant cell lines. Finally, for a conquest cure for the resistance, we demonstrated that the combination therapy of pemetrexed and BEZ235 has significant antitumor effect for the premetrexed resistant cell lines, and that this combination is potential promising therapy to overcome pemetrexed resistance in malignant pleural mesothelioma.

Free Research Field

医歯薬学